...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >The clinical significance of cytomegaloviral inclusions in the allograft kidney.
【24h】

The clinical significance of cytomegaloviral inclusions in the allograft kidney.

机译:同种异体肾中巨细胞病毒包涵体的临床意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Renal allografts are a frequent site of subclinical cytomegalovirus (CMV) infection diagnosed by culture, but histologic inclusions occur in less than 1% of biopsies. The natural history of this subgroup of patients has been reported only occasionally, mostly before the availability of ganciclovir therapy. METHODS: We analyzed the clinical parameters and pathologic findings in 10 patients with CMV inclusions at allograft biopsy. RESULTS: The patients were 29-72 years old, and 9 of 10 (90%) had previous episodes of acute rejection, 3 of whom needed OKT3 administration. Histopathologic examination of the allografts showed interstitial inflammation with tubulitis in 7 of 10 (70%) patients; in 3 of 10 (30%) patients, viral inclusions were present in the glomerular capillary endothelia without any associated inflammatory response. Morphologic criteria for acute transplant glomerulopathy or proliferative glomerulonephritis were not satisfied. Extrarenal viral inclusions were documented in the gastrointestinal tracts of 2 of 10 (20%) patients. The patients were treated with reduced immunosuppression and ganciclovir. Five patients lost their grafts 56.6+/-86.6 days (range, 4-210 days; median, 21 days) after initial diagnosis. The serum creatinine in the remaining five patients was 3.3+/-2.0 mg/dl (range, 1.2-6.5 mg/dl; median, 2.5 mg/dl) 77+/-16 days (range, 56-101 days; median, 77 days) after transplantation. Histopathologic examination showed no residual viral inclusions in 5 of 7 (71.4%) follow-up specimens available for examination. CONCLUSIONS: CMV inclusions in renal allograft biopsies typically occur after treatment for rejection. Ganciclovir eradicates replicative virus, but graft outcome is determined by coexisting acute rejection and chronic allograft nephropathy. Graft loss primarily attributable to CMV was not observed.
机译:背景:肾同种异体移植是通过培养诊断出的亚临床巨细胞病毒(CMV)感染的常见部位,但是组织学夹杂物发生在不到1%的活检组织中。该患者亚组的自然病史仅偶尔报道,主要是在更昔洛韦治疗之前。方法:在同种异体移植活检中,我们分析了10例CMV夹杂物的临床参数和病理结果。结果:患者年龄为29-72岁,每10例中有9例(90%)有过急性排斥反应,其中3例需要使用OKT3。对同种异体移植物的组织病理学检查显示,在10名患者中有7名(70%)患有肾小管炎的间质性炎症。在10名患者中,有3名(30%)的病毒包涵体存在于肾小球毛细血管内皮细胞中,而没有任何相关的炎症反应。不符合急性移植肾小球病或增生性肾小球肾炎的形态学标准。 10名患者中有2名(20%)的胃肠道记录了肾外病毒包涵体。患者接受了降低的免疫抑制和更昔洛韦治疗。初诊后5例患者在56.6 +/- 86.6天(范围:4-210天;中位数:21天)丢失了移植物。其余五名患者的血清肌酐为3.3 +/- 2.0 mg / dl(范围1.2-6.5 mg / dl;中位数2.5 mg / dl)77 +/- 16天(范围56-101天;中位数77天)。组织病理学检查显示,在可检查的7个随访标本中,有5个(71.4%)没有残留病毒包涵体。结论:肾异体移植活检中的CMV夹杂物通常在排斥反应治疗后发生。更昔洛韦根除复制性病毒,但移植物的结局是由急性排斥反应和慢性同种异体移植肾病共存所决定。没有观察到主要归因于CMV的移植物损失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号